Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar ...

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

Abatacept, a CTLA4–Fc fusion protein that modulates T-cell activation, has been developed for the treatment of rheumatoid arthritis. Tay et al. evaluated the effect of abatacept on vaccination ...

A clinical trial found that abatacept is "effective in preventing the onset" of the disease. Abatacept is prescribed to ...

Our objective was to assess the efficacy of infliximab, adalimumab and abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate. The purpose of this type of ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Piscataway, N.J., United States: Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar candidate, KSHB002, has successfully met ...